LYON, France, May 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that The University of Texas M.D. Anderson Cancer Center in Houston, Texas received Institutional Review Board (IRB) approval to participate in EDAP's ongoing ENLIGHT Phase II/III clinical trial of Ablatherm(r)-High Intensity Focused Ultrasound (HIFU) in patients with localized prostate cancer.
